BioNTech SE ADR (BNTX): Price and Financial Metrics
BNTX Price/Volume Stats
| Current price | $104.64 | 52-week high | $188.99 |
| Prev. close | $106.43 | 52-week low | $95.50 |
| Day low | $104.64 | Volume | 470,600 |
| Day high | $106.69 | Avg. volume | 686,865 |
| 50-day MA | $111.71 | Dividend yield | N/A |
| 200-day MA | $124.90 | Market Cap | 25.22B |
BNTX Stock Price Chart Interactive Chart >
BNTX POWR Grades
- BNTX scores best on the Value dimension, with a Value rank ahead of 98.19% of US stocks.
- The strongest trend for BNTX is in Growth, which has been heading down over the past 179 days.
- BNTX's current lowest rank is in the Growth metric (where it is better than 0.42% of US stocks).
BNTX Stock Summary
- BIONTECH SE's market capitalization of $26,144,646,850 is ahead of 91.77% of US-listed equities.
- With a year-over-year growth in debt of -59.79%, BIONTECH SE's debt growth rate surpasses merely 4.13% of about US stocks.
- As for revenue growth, note that BNTX's revenue has grown -52.28% over the past 12 months; that beats the revenue growth of merely 4.89% of US companies in our set.
- Stocks that are quantitatively similar to BNTX, based on their financial statements, market capitalization, and price volatility, are GNFT, BNOX, IMOS, NOK, and IMMP.
- Visit BNTX's SEC page to see the company's official filings. To visit the company's web site, go to www.biontech.de.
BioNTech SE ADR (BNTX) Company Bio
BioNTech SE (/biːˈɒntɛk/ bee-ON-tek; or /baɪˈɒntɛk/ bye-ON-tek [2] short for Biopharmaceutical New Technologies) is a German biotechnology company based in Mainz that develops and manufactures active immunotherapies for patient-specific approaches to the treatment of diseases. It develops pharmaceutical candidates based on messenger ribonucleic acid (mRNA) for use as individualized cancer immunotherapies, as vaccines against infectious diseases and as protein replacement therapies for rare diseases, and also engineered cell therapy, novel antibodies and small molecule immunomodulators as treatment options for cancer. (Source:Wikipedia)
Latest BNTX News From Around the Web
Below are the latest news stories about BIONTECH SE that investors may wish to consider to help them evaluate BNTX as an investment opportunity.
With New COVID-19 Boosters in Tow, Which Is the Better Buy: Pfizer, BioNtech, or Moderna Stock?The Food and Drug Administration (FDA) just approved the updated Omicron-adapted COVID-19 booster shots from Moderna (NASDAQ: MRNA) and the COVID-19 booster that Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) collaborated on. While the news will certainly help the pharmaceutical companies' bottom lines, it's important to look deeper to see if any of these three stocks make a solid investment today. At first glance, Pfizer's stock appears to be a screaming deal. |
Moderna’s Stock Is S&P 500’s Biggest Loser TodayModerna stock dropped 9.1% on Monday despite little fundamental news being reported on the company. The most notable headline involved Noubar Afeyan, a co-founder of Moderna (ticker: MRNA) and board member, who sold 15,000 shares of Moderna for a total value of $1.65 million, according to a filing with the Securities and Exchange Commission made public on Friday. Moderna also gained 8.3% from Monday through Friday of last week, suggesting that today’s move might have simply been the kind of volatility typically associated with Moderna shares. |
Shares of COVID-19 Vaccine Makers Fall After Pfizer CFO Warns of Outlook 'Haircut'Moderna was the worst-performing stock in the S&P 500, and Pfizer shares dropped as well after Pfizer CFO David Denton said the outlook for vaccine rates this year got a significant "haircut." |
UPDATE 2-BioNTech wins up to $90 mln in funding for mpox vaccine developmentGermany's BioNTech announced on Monday a partnership with a global coalition for up to $90 million in funding to support the development of mpox vaccine candidates. BioNTech would initiate an early-to-mid stage trial for the vaccine program BNT166 to prevent mpox, a viral illness that causes skin rashes and could be transmitted to humans through physical contact. The vaccine candidates are based on the same messenger-RNA (mRNA) technology which has been used in its COVID shots developed with partner Pfizer. |
BioNTech and CEPI Announce Partnership to Advance mRNA Mpox Vaccine Development and Support CEPI’s 100 Days MissionBioNTech is initiating a Phase 1/2 clinical trial of the mRNA-based mpox vaccine program, BNT166The Coalition for Epidemic Preparedness Innovations (CEPI) commits funding of up to $90 million for the development of vaccine candidatesData generated by this partnership will contribute to CEPI’s 100 Days Mission, a global effort to accelerate the development of well-tolerated and effective vaccines against future viral threats with pandemic potentialThe partnership is part of BioNTech’s strategy to |
BNTX Price Returns
| 1-mo | -12.10% |
| 3-mo | -2.33% |
| 6-mo | -15.34% |
| 1-year | -18.47% |
| 3-year | 67.13% |
| 5-year | N/A |
| YTD | -30.34% |
| 2022 | -40.60% |
| 2021 | 216.24% |
| 2020 | 140.61% |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...